Published in J Neurol on December 21, 2010
Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome. Clin Exp Immunol (2014) 0.82
Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias (2015) 0.78
Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol (2016) 0.75
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain (2001) 5.04
Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med (1990) 2.54
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry (2000) 1.59
Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry (1996) 1.39
Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry (1993) 1.33
Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol (2004) 1.29
Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) (2003) 1.27
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol (2006) 1.21
Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer (1996) 1.11
Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology (1994) 1.09
Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol (2003) 1.09
Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol (2006) 1.04
Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. J Neurol Sci (2008) 0.93
Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol (1999) 0.91
Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol (1995) 0.90
Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol (2007) 0.88
Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol (1998) 0.87
Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol (2009) 1.90
Cyclosporine A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue. Brain (2008) 1.65
High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany. J Neurol (2008) 1.37
The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. Neurology (2010) 1.36
Coenzyme Q10 deficiency and isolated myopathy. Neurology (2006) 1.32
High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol (2000) 1.30
140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord (2006) 1.30
Scapuloperoneal syndrome type Kaeser and a wide phenotypic spectrum of adult-onset, dominant myopathies are associated with the desmin mutation R350P. Brain (2007) 1.26
FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet (2004) 1.24
Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics (2007) 1.18
Characterization of neuronal nicotinic acetylcholine receptors in the membrane of unmyelinated human C-fiber axons by in vitro studies. J Neurophysiol (2003) 1.00
Myotonic dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, Naarden, The Netherlands. Neuromuscul Disord (2011) 0.98
Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology (2000) 0.94
GNE protein expression and subcellular distribution are unaltered in HIBM. Neurology (2007) 0.94
Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord (2009) 0.90
De novo missense mutation in a constitutively expressed exon of the slow alpha-tropomyosin gene TPM3 associated with an atypical, sporadic case of nemaline myopathy. Neuromuscul Disord (2002) 0.86
Low level of intracortical inhibition in children shown by transcranial magnetic stimulation. Neuropediatrics (2004) 0.85
The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes. Int J Cardiol (2012) 0.84
Pain in adult patients with Pompe disease: a cross-sectional survey. Mol Genet Metab (2013) 0.83
C283Y mutation in the gamma-sarcoglycan gene in Greek Gypsies with severe limb girdle muscular dystrophy. Eur J Neurol (2010) 0.82
Genetic identity of Marinesco-Sjögren/myoglobinuria and CCFDN syndromes. Neurology (2002) 0.82
Side effects of anesthesia in DM2 as compared to DM1: a comparative retrospective study. Eur J Neurol (2010) 0.82
A synonymous codon change in the LMNA gene alters mRNA splicing and causes limb girdle muscular dystrophy type 1B. J Med Genet (2003) 0.82
Spinal decompressive procedures and dorsal compartment injuries: comparative biomechanical study in canine cadavers. Am J Vet Res (1988) 0.82
Facing the genetic heterogeneity in neuromuscular disorders: linkage analysis as an economic diagnostic approach towards the molecular diagnosis. Neuromuscul Disord (2005) 0.82
Demyelinating disease of central and peripheral nervous systems associated with a A8344G mutation in tRNALys. Neuromuscul Disord (2009) 0.81
[Diagnosis and therapy of late onset Pompe disease]. Nervenarzt (2013) 0.80
No muscle involvement in myoclonus-dystonia caused by epsilon-sarcoglycan gene mutations. Eur J Neurol (2008) 0.80
Phenotypic variability in siblings with calpainopathy (LGMD2A). Acta Myol (2008) 0.80
Sleep-related symptoms and sleep-disordered breathing in adult Pompe disease. Eur J Neurol (2014) 0.79
Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis. Lancet (1999) 0.78
Long-term MRI and clinical follow-up of symptomatic and presymptomatic carriers of dysferlin gene mutations. Acta Myol (2005) 0.78
Muscle MRI in FHL1-linked reducing body myopathy. Neuromuscul Disord (2009) 0.77
Respiratory insufficiency as a presenting symptom of LGMD2D in adulthood. Acta Myol (2004) 0.76
[Diagnosis and therapy of vasculitic neuropathy. Consensus statement of the German Centers for Neuromuscular Disease]. Fortschr Neurol Psychiatr (2003) 0.76
Brain imaging and neuropsychology in late-onset dementia due to a novel mutation (R93C) of valosin-containing protein. Clin Neuropathol (2007) 0.76
Neurodegeneration-associated proteins and inflammation in sporadic inclusion-body myositis. Adv Exp Med Biol (2001) 0.76
LGMD 2I due to the common mutation 826C>A in the FKRP gene presenting as myopathy with vacuoles and paired-helical filaments. Acta Myol (2006) 0.75
Prion codon 129 homozygosity and sporadic inclusion body myositis. Neurology (2001) 0.75
Chronic hypertrophic pyloric gastropathy as a cause of pyloric obstruction in the dog. J Am Vet Med Assoc (1985) 0.75
[Congenital and endogenous endocrine myopathy]. Z Rheumatol (2011) 0.75
[Neuromuscular signal transmission in adulthood. Current facets of acquired and hereditary disorders]. Nervenarzt (2011) 0.75
Unique PABPN1 gene mutation in a large Bulgarian family with OPMD. J Neurol (2008) 0.75
Successful treatment of muscle sarcoidosis with thalidomide. Acta Myol (2003) 0.75
Urinary diversion. Vet Clin North Am Small Anim Pract (1984) 0.75
[Educational and Professional Qualifications of Adults With Myotonic Dystrophies - A Misleading Perception by the Myopathic Face?]. Fortschr Neurol Psychiatr (2016) 0.75
Ten-year follow-up in a case series of integrative botulinum toxin intervention in adolescents with chronic daily headache and associated muscle pain. Neuropediatrics (2012) 0.75
Effect of sera of patients with genitourinary tract cancers on transformation of lymphocytes stimulated with anti-thymocyte globulin. Natl Cancer Inst Monogr (1978) 0.75
Glycogen storage diseases of all types. J Inherit Metab Dis (2015) 0.75
Use of serum beta-chain human chorionic gonadotropin in the management of testis tumor. Natl Cancer Inst Monogr (1978) 0.75
Influence of age on metabolism of testosterone, dihydrotestosterone, and 3-alpha-androstanediol in muscle biopsies from patients with neuromuscular diseases. Arch Gerontol Geriatr (2004) 0.75
Ureterocolonic anastomosis in clinically normal dogs. Am J Vet Res (1988) 0.75
Treatment of severely comminuted diaphyseal fractures in the dog, using standard bone plates and autogenous cancellous bone graft to span fracture gaps: 11 cases (1979-1983). J Am Vet Med Assoc (1986) 0.75
[Metabolic myopathies - an overview]. Pathologe (2009) 0.75
Vitamin B-6 metabolism as affected by exercise in trained and untrained women fed diets differing in carbohydrate and vitamin B-6 content. Am J Clin Nutr (1987) 0.75
[Myalgia and myopathy]. Z Rheumatol (2015) 0.75
[The Spectrum of Neuromyotonia: Clinics, Therapy and Outcome]. Fortschr Neurol Psychiatr (2015) 0.75
[Lipid storage myopathies. A clinical and pathobiochemical challenge]. Nervenarzt (2010) 0.75
Furosemide overdose and maximal allowable weight standards. Mil Med (1989) 0.75
Pylorectomy and gastroduodenostomy in the dog: technique and clinical results in 28 cases. J Am Vet Med Assoc (1985) 0.75
[New insights in pathogenesis and therapy of sporadic inclusion body myositis (s-IBM)]. Nervenarzt (2001) 0.75